Valuation: Moderna, Inc.

Market Cap 32.46B 28.43B 26.18B 24.3B 46.15B 3,096B 46.77B 313B 122B 1,520B 122B 119B 5,269B P/E 2026 *
-9.46x
P/E 2027 * -17.3x
Enterprise Value 28.85B 25.27B 23.27B 21.6B 41.02B 2,752B 41.58B 279B 108B 1,351B 108B 106B 4,684B EV / Sales 2026 *
13.8x
EV / Sales 2027 * 11.9x
Free-Float
92.69%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Moderna, Inc.

1 day-2.85%
1 week+12.60%
Current month+12.60%
1 month+65.66%
3 months+57.36%
6 months+119.71%
Current year+167.40%
1 week 68.87
Extreme 68.8655
85.6
1 month 45.4
Extreme 45.4
85.6
Current year 29.81
Extreme 29.81
85.6
1 year 22.28
Extreme 22.28
85.6
3 years 22.28
Extreme 22.28
170.47
5 years 22.28
Extreme 22.28
497.49
10 years 11.54
Extreme 11.54
497.49
Manager TitleAgeSince
Chief Executive Officer 54 01/03/2011
Director of Finance/CFO 49 06/09/2022
President 50 01/11/2024
Director TitleAgeSince
Chairman 63 01/02/2012
Director/Board Member 54 01/03/2011
Director/Board Member 69 11/12/2019
Date Insider Type Main position Quantity % Market Cap.
06-15Fiscal year

Chairperson

160,008 0.0403%
06-05Fiscal year

Chief Financial Officer

29,301 0.0074%
06-05Fiscal year

General Counsel

29,301 0.0074%
Change 5-day change 1-year change 3-year change Capi.($)
-2.72%+12.60%+163.73%-33.66% 32.46B
+3.19%+7.17%+24.18%-3.50% 66.11B
-0.24%-3.13%+49.38%+223.97% 55.3B
+1.21%+42.20%+42.20%+42.20% 42.44B
-0.21%+7.44%-48.93%-54.50% 41.28B
+0.28%-3.35%+60.47%-24.08% 30.78B
+1.56%+3.60%+74.58%+89.21% 23.1B
-3.65%+8.93%+1.16%+184.50% 20.06B
-0.04%+3.85%+67.76%+135.89% 17.19B
+0.81%+4.94%+79.68%+362.76% 15.23B
Average +0.05%+5.60%+51.42%+92.28% 34.39B
Weighted average by Cap. +0.45%+4.33%+44.77%+68.27%

Financials

2026 *2027 *
Net sales 2.09B 1.83B 1.69B 1.56B 2.97B 199B 3.01B 20.18B 7.85B 97.84B 7.85B 7.68B 339B 2.53B 2.21B 2.04B 1.89B 3.6B 241B 3.64B 24.42B 9.5B 118B 9.5B 9.29B 411B
Net income -3.4B -2.98B -2.75B -2.55B -4.84B -325B -4.91B -32.87B -12.79B -159B -12.78B -12.5B -553B -1.83B -1.61B -1.48B -1.37B -2.61B -175B -2.64B -17.72B -6.9B -85.92B -6.89B -6.74B -298B
Net Debt -3.61B -3.16B -2.91B -2.7B -5.13B -344B -5.2B -34.82B -13.55B -169B -13.54B -13.24B -585B -2.27B -1.99B -1.84B -1.7B -3.23B -217B -3.28B -21.97B -8.55B -107B -8.54B -8.36B -369B
Logo Moderna, Inc.
Moderna, Inc. is a biotechnology company specialized in research and development of therapeutics and vaccines for cancer, infectious, autoimmune and cardiovascular diseases. Net sales break down by type of revenue as follows: - revenue from product sales (96.1%); - revenue from collaboration agreements (1.5%); - revenue from royalties and licensing (1.3%); - revenue from grants (1.1%). At the end of 2024, the group's portfolio comprises 37 products in clinical development, of which 10 in phase I, 18 in phase II and 9 in phase III, 3 products in preclinical development, and 4 products in commercial phase. Net sales are distributed geographically as follows: the United States (55.1%), Europe (18.5%) and other (26.4%).
Employees
4,700
Date Price Change Volume
07/07/26 $79.00 -3.43% 3,485,590
06/07/26 $81.80 +2.56% 17,296,875
02/07/26 $79.76 +10.01% 14,111,998
01/07/26 $72.50 +3.53% 9,275,292
30/06/26 $70.03 +0.47% 11,805,910
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
23
Last Close Price
81.80USD
Average target price
47.00USD
Spread / Average Target
-42.54%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. MRNA Stock